Adenovirus-based Solutions for Environmental Remediation and Sustainability

Publication ID: 24-11857620_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Adenovirus-based Solutions for Environmental Remediation and Sustainability,” Published Technical Disclosure No. 24-11857620_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857620_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,620.

Summary of the Inventive Concept

This inventive concept leverages the core technology of the original patent to develop novel applications in environmental remediation, industrial processes, and agricultural sustainability, utilizing replication-defective adenovirus-based systems to enhance microorganism-mediated pollutant degradation, water quality monitoring, and crop yield improvement.

Background and Problem Solved

The original patent focused on inducing immunity against SARS-CoV-2 using spike (S) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus. However, this technology has broader potential beyond vaccine development. The inventive concept addresses the limitations of current environmental remediation methods, industrial processes, and agricultural practices, which often rely on inefficient or unsustainable approaches. By applying the adenovirus-based technology to these new fields, we can develop more effective and eco-friendly solutions.

Detailed Description of the Inventive Concept

The new claims describe adenovirus-based systems for treating wastewater, reducing pollutants in industrial processes, bioremediation, monitoring water quality, and improving crop yields. These systems utilize replication-defective adenoviruses encoding spike protein sequences optimized for cell surface expression and nucleocapsid proteins fused to endosomal targeting sequences. The adenoviruses are used to express these proteins in microorganisms, enhancing their ability to degrade pollutants, fix nitrogen, and promote plant growth. The inventive concept enables the development of more efficient and sustainable environmental remediation methods, industrial processes, and agricultural practices.

Novelty and Inventive Step

The novelty of this inventive concept lies in the application of adenovirus-based technology to entirely new fields, leveraging the original patent's core technology to address distinct problems. The inventive step is the recognition of the potential for adenovirus-mediated protein expression in microorganisms to drive sustainable solutions in environmental remediation, industrial processes, and agriculture.

Alternative Embodiments and Variations

Alternative embodiments of this inventive concept could include the use of different adenovirus serotypes, varying the spike protein sequence or nucleocapsid protein fusion, or incorporating additional genes to further enhance microorganism-mediated pollutant degradation or plant growth promotion. Variations could also involve the development of adenovirus-based systems for other environmental or industrial applications, such as bioremediation of contaminated soil or groundwater.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the environmental remediation, industrial processes, and agricultural sectors. The market for sustainable solutions in these areas is growing rapidly, driven by increasing concerns about environmental degradation, climate change, and food security. Adenovirus-based systems could provide a competitive advantage in these markets, offering more efficient, eco-friendly, and cost-effective solutions for wastewater treatment, pollutant reduction, bioremediation, and crop yield improvement.

CPC Classifications

SectionClassGroup
A A61 A61K39/215
A A61 A61K39/39
C C12 C12N15/86
A A61 A61K2039/545
A A61 A61K2039/55505
A A61 A61P31/14
C C12 C12N2710/10343
C C12 C12N2770/20022
C C12 C12N2770/20034

Field of Art

Biotechnology and molecular virology, with expertise in viral vector design, protein engineering, and genetic modification of microorganisms for therapeutic, environmental, and agricultural applications

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with advanced degrees in molecular biology, virology, or bioengineering, possessing knowledge of adenovirus vector systems, protein expression techniques, and interdisciplinary applications of genetic engineering

Obviousness Rationale

The PTD represents a predictable extension of the source patent's core adenovirus-based protein expression technology by applying the fundamental viral vector design to novel environmental and agricultural contexts. A PHOSITA would recognize the inherent versatility of replication-defective adenovirus systems for protein delivery and expression across different biological domains. The technical principles of spike and nucleocapsid protein manipulation demonstrated in the original SARS-CoV-2 vaccine context directly translate to other protein expression and cellular modification applications.

Obvious Combinations & Variations

Source Patent Element
Replication-defective adenovirus encoding spike and nucleocapsid proteins for immune response
PTD Variation
Replication-defective adenovirus encoding spike and nucleocapsid proteins for enhancing microorganism performance in environmental and agricultural contexts
Obviousness Reasoning
Known viral vector technology applied to a predictable alternative domain with expected results of cellular protein expression and modification
Source Patent Element
Protein sequence optimization for cellular targeting and expression
PTD Variation
Spike protein sequences optimized for cell surface expression in microorganisms for pollutant degradation and crop enhancement
Obviousness Reasoning
Routine protein engineering technique extending known cellular targeting strategies to new biological systems
Source Patent Element
Nucleocapsid protein delivery mechanism
PTD Variation
Nucleocapsid proteins fused with endosomal targeting sequences for enhanced microorganism functionality
Obviousness Reasoning
Predictable protein modification technique using well-established molecular biology approaches to improve cellular protein localization and function
Source Patent Element
Vaccine composition with specific viral vector design
PTD Variation
Vaccine-like composition for introducing genetic modifications in industrial and agricultural microorganisms
Obviousness Reasoning
Logical extension of viral vector delivery principles to non-medical biological engineering contexts
Source Patent Element
Protein expression in cellular systems for immune response
PTD Variation
Protein expression in microorganisms for environmental remediation and agricultural enhancement
Obviousness Reasoning
Predictable application of established genetic modification techniques to solve distinct technical challenges
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857620 and the principles of viral vector design, the present published technical disclosure demonstrates that the claimed variations in environmental and agricultural applications of adenovirus-based protein expression systems would have been obvious to a person having ordinary skill in the art at the time of invention, thereby constituting prior art that anticipates and renders obvious substantially similar technical approaches in genetic modification and biological engineering.

Original Patent Information

Patent NumberUS 11,857,620
TitleMethod of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
Assignee(s)ImmunityBio, Inc.